EP Patent

EP3401314A1 — Covalent inhibitors of kras g12c

Assigned to Araxes Pharma LLC · Expires 2018-11-14 · 8y expired

What this patent protects

Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

USPTO Abstract

Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

Drugs covered by this patent

Patent Metadata

Patent number
EP3401314A1
Jurisdiction
EP
Classification
—
Expires
2018-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Araxes Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.